Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01807156 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
A Phase 2 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT01807156 is a Phase 2 study that was terminated before completion, run by Emory University. The registered enrollment target is 7 participants.
The verdict
NCT01807156, a Phase 2 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about the effect of the investigational agent tivozanib on the control of the tumor growth in hepatocellular (liver) cancer. The investigators also plan to collect information on the likelihood to develop side effects while on this treatment. Tivozanib is an oral medication (pill) taken once a day. This medication is designed to stop the tumor from developing new blood vessels.
Interventions
- DRUG Tivozanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2013-03 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01807156
The ClinicalTrials.gov registry entry for NCT01807156 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tivozanib is the first listed.
NCT01807156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01807156 about?
NCT01807156 is a clinical study titled "Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer". The purpose of this study is to learn about the effect of the investigational agent tivozanib on the control of the tumor growth in hepatocellular (liver) cancer. The investigators also plan to collect information on the likelihood to develop side effects while on this treatment. Tivozanib is an ora...
What is the current status of trial NCT01807156?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2013-03. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01807156?
The interventions under investigation include: Tivozanib (DRUG).
Who is sponsoring clinical trial NCT01807156?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.